Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 1
2013 3
2014 6
2015 2
2016 4
2017 4
2018 5
2019 4
2020 7
2021 8
2022 6
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Among authors: schuckman ak. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network; Weinstein JN, Kwiatkowski DJ, Lerner SP. Robertson AG, et al. Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Cell. 2017. PMID: 28988769 Free PMC article.
Reply by Authors.
Haque TF, Hui A, You J, Ma R, Nguyen JH, Lei X, Cen S, Aron M, Collins JW, Djaladat H, Ghazi A, Yates KA, Abreu AL, Daneshmand S, Desai MM, Goh AC, Hu JC, Lebastchi AH, Lendvay TS, Porter J, Schuckman AK, Sotelo R, Sundaram CP, Gill IS, Hung AJ. Haque TF, et al. Among authors: schuckman ak. Urol Pract. 2022 Nov;9(6):541. doi: 10.1097/UPJ.0000000000000344.03. Epub 2022 Sep 7. Urol Pract. 2022. PMID: 37145829 No abstract available.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Narayan VM, et al. Among authors: schuckman ak. J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5. J Urol. 2024. PMID: 38704840 Clinical Trial.
Reply by Authors.
Mitra AP, Cai J, Miranda G, Bhanvadia S, Quinn DI, Schuckman AK, Djaladat H, Daneshmand S. Mitra AP, et al. Among authors: schuckman ak. J Urol. 2022 Feb;207(2):313. doi: 10.1097/JU.0000000000002242.02. Epub 2021 Nov 8. J Urol. 2022. PMID: 34994654 No abstract available.
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Mitra AP, et al. Among authors: schuckman ak. Eur Urol. 2022 Mar;81(3):223-228. doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18. Eur Urol. 2022. PMID: 34933753 Free PMC article.
Enhanced recovery after cystectomy in patients with preoperative narcotic use.
Ghodoussipour S, Ghoreifi A, Katebian B, Cameron BH, Mitra AP, Cai J, Miranda G, Schuckman AK, Daneshmand S, Djaladat H. Ghodoussipour S, et al. Among authors: schuckman ak. Can Urol Assoc J. 2021 Oct;15(10):E563-E568. doi: 10.5489/cuaj.7007. Can Urol Assoc J. 2021. PMID: 33999800 Free PMC article. Review.
Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S. Bazargani ST, et al. Among authors: schuckman ak. Urol Oncol. 2019 Jan;37(1):1-11. doi: 10.1016/j.urolonc.2018.09.008. Epub 2018 Nov 20. Urol Oncol. 2019. PMID: 30470611 Free PMC article. Review.
39 results